RT Journal Article
SR Electronic
T1 Modeling Pulmonary Cystic Fibrosis in a Human Lung Airway-on-a-chip
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.15.21260407
DO 10.1101/2021.07.15.21260407
A1 Roberto Plebani
A1 Ratnakar Potla
A1 Mercy Soong
A1 Haiqing Bai
A1 Zohreh Izadifar
A1 Amanda Jiang
A1 Renee N. Travis
A1 Chaitra Belgur
A1 Mark J. Cartwright
A1 Rachelle Prantil-Baun
A1 Pawan Jolly
A1 Sarah E. Giplin
A1 Mario Romano
A1 Donald E. Ingber
YR 2021
UL http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260407.abstract
AB Background Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), which results in impaired airway mucociliary clearance, inflammation, infection, and respiratory insufficiency. The development of new therapeutics for CF are limited by the lack of reliable preclinical models that recapitulate the structural, immunological, and bioelectrical features of human CF lungs.Methods We leveraged organ-on-a-chip technology to develop a microfluidic device lined by primary human CF bronchial epithelial cells grown under an air-liquid interface and interfaced with pulmonary microvascular endothelial cells (CF Airway Chip) exposed to fluid flow. The responses of CF and healthy Airway Chips were analyzed in the presence or absence of polymorphonuclear leukocytes (PMNs) and the bacterial pathogen, Pseudomonas aeruginosa.Results The CF Airway Chip faithfully recapitulated many features of the human CF airways, including enhanced mucus production, increased cilia density and a higher ciliary beating frequency compared to chips lined by healthy bronchial epithelial cells. The CF chips also secreted higher levels of IL-8, which was accompanied by enhanced PMN adhesion to the endothelium and transmigration into the airway compartment. In addition, CF Airway Chips provided a more favorable environment for Pseudomonas aeruginosa growth, which resulted in enhanced secretion of inflammatory cytokines and recruitment of PMNs to the airway.Conclusions The human CF Airway Chip may provide a valuable preclinical tool for pathophysiology studies as well as for drug testing and personalized medicine.Competing Interest StatementDonald E. Ingber is a founder, board member, scientific advisory board chair, and equity holder in Emulate, Inc.Funding StatementThis work was supported by the Cystic Fibrosis Foundation (award: INGBER18XX0), the Wyss Institute for Biologically Inspired Engineering at Harvard University, and Programma Operativo Nazionale Ricerca e Innovazione (D56C19000330005).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB/oversight body: Harvard Faculty of Medicine Office of Regulatory Affairs and Research Compliance. The Institutional Review Board (IRB) of the Harvard Faculty of Medicine determined this work to be not human subjects research as defined by DHHS or FDA regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the submission and will be made available upon request